title: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
abstract: Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As(2)0(3)) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of As(2)0(3) + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As(2)0(3) alone. Correlative studies were undertaken of As(2)0(3) and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As(2)O(3) + 1,000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As(2)0(3), and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As(2)0(3) + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As(2)0(3) + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma.
authors.affiliation: Sylvester Comprehensive Cancer Center, University of Miami, Florida, USA.
authors.forename: Nizar J
authors.initials: NJ
authors.lastname: Bahlis
authors.forename: Jennifer
authors.initials: J
authors.lastname: McCafferty-Grad
authors.forename: Ileana
authors.initials: I
authors.lastname: Jordan-McMurry
authors.forename: Jim
authors.initials: J
authors.lastname: Neil
authors.forename: Isildinha
authors.initials: I
authors.lastname: Reis
authors.forename: Mohamed
authors.initials: M
authors.lastname: Kharfan-Dabaja
authors.forename: James
authors.initials: J
authors.lastname: Eckman
authors.forename: Mark
authors.initials: M
authors.lastname: Goodman
authors.forename: Hugo F
authors.initials: HF
authors.lastname: Fernandez
authors.forename: Lawrence H
authors.initials: LH
authors.lastname: Boise
authors.forename: Kelvin P
authors.initials: KP
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000097:blood / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D001205:Ascorbic Acid / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005240:Feasibility Studies; D005260:Female; D005978:Glutathione / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010087:Oxides / Q000008:administration & dosage; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D001152:Arsenicals; D010087:Oxides; D005978:Glutathione; D001205:Ascorbic Acid; D000077237:Arsenic Trioxide